---
title: "BSF Enterprise Signs Exclusive Global ETSYL® Skincare Commercialisation Deal"
publisher: "Share Talk"
author: "sharetalk"
published: "2026-08-11T07:26:27+00:00"
modified: "2026-08-11T07:32:18+00:00"
date: 2026-08-11
canonical: "https://www.share-talk.com/bsf-enterprise-signs-exclusive-global-etsyl-skincare-commercialisation-deal/"
category: "Health"
categories: ["Health", "Healthcare", "Pharmaceutical"]
tags: ["BSF Enterprise", "BSFA", "Che Connon", "Elemental Leather™", "Etsyl", "Lab-Grown", "lab-grown leather", "luxury skincare brand", "SCHAKAU", "T-Rex Leather™", "tissue engineering techniques"]
image: "https://i0.wp.com/www.share-talk.com/wp-content/uploads/2026/08/BSF_ETSYL_Transaction_Highlights_1212x639.png?fit=1212%2C639&quality=80&ssl=1"
format: "news"
language: "en-GB"
---

# BSF Enterprise Signs Exclusive Global ETSYL® Skincare Commercialisation Deal

**Published:** August 11, 2026
**Author:** sharetalk
**Categories:** Health, Healthcare, Pharmaceutical
**Tags:** BSF Enterprise, BSFA, Che Connon, Elemental Leather™, Etsyl, Lab-Grown, lab-grown leather, luxury skincare brand, SCHAKAU, T-Rex Leather™, tissue engineering techniques
**Featured image:** ![](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2026/08/BSF_ETSYL_Transaction_Highlights_1212x639.png?fit=1212%2C639&quality=80&ssl=1)

---

[BSF Enterprise PLC (LON: BSFA)](https://www.investegate.co.uk/announcement/rns/bsf-enterprise--bsfa/worldwide-commercialisation-of-etsyl/9714331) has signed heads of terms with **SCHAKAU Managementberatung GmbH** for the worldwide exclusive commercialisation of its proprietary bioactive peptide **ETSYL®** across cosmetics, skincare, dermocosmetics and luxury beauty.

The agreement grants SCHAKAU exclusive global rights for an initial **10-year term**, subject to meeting agreed annual volume targets following a 12-month ramp-up period.

SCHAKAU has committed around **€300,000** towards market development, including clinical claims, regulatory work, branding and international distribution, while also covering downstream product compliance and efficacy testing costs.

BSF will retain **100% ownership of the intellectual property** and will supply ETSYL® through its wholly owned subsidiary **3D Bio-tissues**, creating a direct manufacturing revenue stream.

**Key Transaction Highlights:**

●    Exclusive 10-Year Global Term: SCHAKAU receives exclusive worldwide rights in cosmetics and luxury beauty for an initial 10-year period, strictly conditional upon achieving agreed annual commercial volume targets following an initial 12-month ramp-up period.

●    Funded Commercialisation: SCHAKAU has allocated a dedicated market development budget estimated at €300,000 to fund clinical claim substantiation, regulatory compliance, brand creation, and international distribution capital.

●    Downstream Expenses: SCHAKAU is solely responsible, at its own expense, for all finished consumer product notifications (including CPNP/SCPN portal filings), Cosmetic Product Safety Reports (CPSR), Responsible Person (RP) representations, and clinical efficacy testing.

●    Direct Supply Revenue Stream & Expected Timing: BSF will supply compliant bioactive ETSYL® under a structured, dose-based volume schedule, securing commercial manufacturing margins for BSF’s 100% subsidiary, 3D Bio-tissues Ltd. Initial raw material supply revenues are expected during the 12-month product compilation phase ahead of retail launch.

●    50:50 Third-Party Licensing Split: Net licensing income from third-party brand integrations will be split 50:50, after deducting external compliance and international patent prosecution and maintenance costs, directly protecting BSF’s historical and ongoing patent investments.

●    100% IP Retention: BSF retains absolute ownership of all patents, trade secrets, manufacturing know-how, and underlying technology related to ETSYL®.

Net licensing income from third-party cosmetic brand integrations will be split **50:50** between BSF and SCHAKAU after certain external compliance and patent costs.

ETSYL® was originally developed to stimulate cell growth and collagen production in tissue engineering applications, but BSF identified its potential as a high-value active ingredient for premium anti-ageing skincare.

SCHAKAU plans to launch ETSYL® initially through its **HANDS OF GOD** luxury skincare brand before pursuing wider B2B licensing opportunities with global cosmetics companies.

Chief executive **Che Connon** said the partnership provides BSF with a capital-light route into the global luxury skincare market while retaining ownership of the underlying technology and generating both supply and licensing revenues.

---

**Original URL:** https://www.share-talk.com/bsf-enterprise-signs-exclusive-global-etsyl-skincare-commercialisation-deal/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*
